Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 4Completed 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 5003Neoplasms 4197Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2264Colorectal Neoplasms 2052Lung Neoplasms 1705Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1381Neoplasm Metastasis 1373Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1192Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 895Brain Neoplasms 876Stomach Neoplasms 855Recurrence 852Carcinoma, Hepatocellular 846Glioblastoma 841Lymphoma, Large B-Cell, Diffuse 771Rectal Neoplasms 759Uterine Cervical Neoplasms 728Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Bile Duct Diseases × Clear all
NCT02115542 2021-10-12

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 11 charts
Gastrointestinal

Bile Duct Diseases, Bile Duct Neoplasms, Carcinoma, Gallbladder Diseases, Gallbladder Neoplasms, Neoplasm Metastasis

NCT00930410 2013-03-20

EMID

Institut Paoli-Calmettes

Phase NA Completed
50 enrolled
Gastrointestinal

Bile Duct Diseases, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡